A 7-day course of antibiotics for patients hospitalized with bloodstream infections was just as effective as a 14-day course, ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Medical experts have emphasised that people suffering from parasitic worm infections should use prescribed antiparasitic ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

According to the CDC, respiratory infections caused by the bacteria Mycoplasma pneumoniae have increased in the U.S. over the ...

GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a ...

Reishi (G. lucidum) has been used for centuries in the traditional medicine system in Asia. This article examines the ...

However, their value in the management of uncomplicated skin infections is not yet clearly defined. This literature review discusses various topical antibiotic treatment options for uncomplicated ...

Embedding discharge orders that reflected the latest guidelines helped drive a dramatic drop in the duration of antibiotics ...

Clarametyx reports progress on study of antibody therapy CMTX-101 for infections associated with CF, to begin phase 2a portion of the trial: Columbus, Ohio Saturday, October 19, 2 ...

Rwanda's outbreak of the deadly Marburg virus is easing after vaccinations of the most vulnerable people including healthcare ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...